Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 09:00 AM ET – House Price Index (YoY) (Mar)

✓ 09:00 AM ET – S&P/CS HPI Composite - 20 s.a. (MoM) (Mar)

✓ 10:00 AM ET – 3 & 6 - Month Bill Auction

✓ 10:30 AM ET – Dallas Fed Mfg Business Index (May)

✓ 01:00 PM ET – M2 Money Supply (MoM)

PREMARKET SNAPSHOT 📈

US stock futures were mostly flat on Tuesday, with tech stocks outperforming ahead of an inflation report.

SECTOR SNAPSHOT ✨

Market dips today, most sectors down with Real Estate hardest hit. Only bright spot is tech, up slightly..

Unusual Volume

📈 Netcapital Inc (NCPL) jumped 10.13% to $0.19 on a whopping 191.35 million shares traded after it announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A-2 warrants to purchase up to an aggregate of 14,320,000 shares of common stock of the Company originally issued in December 2023, having an exercise price of $0.25 per share, at a reduced exercise price of $0.155 per share.

📈 Investors went wild, sending Cue Health Inc (HLTH) stock declining -1.91% to $0.09 on a massive volume of 160.21 million shares.

📈 Abnormal activity shook Nuburu Inc (BURU), pushing it up 19.68% to $0.17 on a whopping 153.06 million shares traded.

📈 OneMedNet Corp. (ONMD) stock recently closed 56.46% upper at $2.30 on substantial volume of 136.21 million shares. This unusual activity came after company announced a greater than five (5)-fold expansion of its proprietary iRWD™ network and platform.

📈 Yoshitsu Co Ltd ADR (TKLF) increase by 31.58% in a single trading session, with abnormally high trading volume of 84.5 million shares.

Premarket Movers

Insmed Inc (INSM) grew over +130.64% at $49.76 in pre-market trading today. INSM announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.

Gamestop Corporation (NYSE: GME) shares are trading up +22.11% at $23.2 at the time of writing. Company’s 52-week ranged between $9.95 to $64.83. Analysts have a consensus price target of $6.20. The videogame retailer revealed that it had raised over $900 million from selling its shares during the market rally earlier this month.

Pineapple Energy Inc (PEGY) stock soared +21.45% to $0.215 in the pre-market trading. PEGY announced recently that its New York-based subsidiary SUNation signed a 1.95-megawatt project. SUNation will begin work on this large-scale commercial installation in early July.

Important FDA 

Recently Announced

Abeona Therapeutics (ABEO): On April 22nd, Abeona received a Complete Response Letter (CRL) for their Pz-cel treatment for recessive dystrophic epidermolysis bullosa. This means the FDA requires further data before considering approval.

Novo Nordisk (NVO): On May 24th, an FDA panel voted against recommending approval for Awiqli (Insulin Icodec) for treating adult diabetes. This is a setback for Novo Nordisk, but not the end of the road for the drug.

Positive Development

Bristol-Myers Squibb (BMY): Breyanzi received a full approval on May 16th for treating relapsed or refractory follicular lymphoma. This provides a new treatment option for patients battling this specific type of cancer.

Upcoming Announcements

Daiichi Sankyo & AstraZeneca (AZN.L, AZN): A verdict is expected on May 30th regarding the expanded use of Enhertu for treating adult patients with specific HER2-positive tumors. Both companies will be waiting anxiously to see if the FDA approves this broader application.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.